| Autor: |
Yuka Kawaji‐Kanayama, Tsutomu Kobayashi, Ayako Muramatsu, Hitoji Uchiyama, Nana Sasaki, Nobuhiko Uoshima, Mitsushige Nakao, Ryoichi Takahashi, Kazuho Shimura, Hiroto Kaneko, Miki Kiyota, Katsuya Wada, Yoshiaki Chinen, Koichi Hirakawa, Shin‐ichi Fuchida, Chihiro Shimazaki, Yayoi Matsumura‐Kimoto, Shinsuke Mizutani, Taku Tsukamoto, Yuji Shimura, Shigeo Horiike, Masafumi Taniwaki, Junya Kuroda, Kyoto Clinical Hematology Study Group (KOTOSG) Investigators |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Cancer Reports, Vol 5, Iss 2, Pp n/a-n/a (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2573-8348 |
| DOI: |
10.1002/cnr2.1476 |
| Popis: |
Abstract Background Combinatory strategies with carfilzomib (CFZ), a second‐generation proteasome inhibitor, plus dexamethasone (DEX) with or without lenalidomide (LEN) have shown promising efficacy for patients with relapsed/refractory multiple myeloma (RRMM) in pivotal clinical trials. However, their effects on patients who were resistance to bortezomib (BTZ) and/or LEN have not been fully evaluated in a daily practice setting. Aims To evaluate the real‐world efficacy and safety of CFZ‐based treatments; that is, CFZ with LEN plus DEX (KRD therapy) and CFZ with DEX (KD therapy), in Asian patients, we conducted a multicenter pilot prospective observational study in the Kyoto Clinical Hematology Study Group. Methods and Results All 50 patients with RRMM enrolled in this study were treated with CFZ‐based treatments between 2017 and 2019. KRD and KD were administered to 31 and 19 patients, respectively. The overall response rates (ORRs) were 80.6% with KRD and 73.7% with KD. Two‐year progression‐free survival (PFS) and overall survival (OS) were 58.5% and 79.7% with KRD, and 23.1% and 52.6% with KD. By multivariate analysis, refractoriness to BTZ and to LEN were identified as independent unfavorable factors for both PFS and OS. The common non‐hematologic AEs included hypertension (42.0%), fever (24.0%), fatigue (24.0%), and infection (16.0%). No serious heart failure was observed. This study is registered as UMIN000025108. Conclusion This study suggests the need of the development of novel CFZ‐containing strategy which can overcome the refractoriness to BTZ and/or LEN, while both KRD and KD were shown to be mostly feasible in Asian patients in a daily practice setting. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text